ANAPC10

Across TCGA pan-cancer cohorts, ANAPC10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANAPC10 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANAPC10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANAPC10 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where ANAPC10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.295	0.531	.007	20	view →
HNSC	DFS	Median	IV	0.639	0.897	.005	10	view →
UCEC	DFS	Median	All	1.000	0.932	.023	6	view →
GBM	DFS	Median	All	0.658	0.772	.015	4	view →
LSCC	OS	Median	All	0.793	1.000	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANAPC10–PDAC (OS)

Open the PDAC breakdown →